194 related articles for article (PubMed ID: 15734867)
1. Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11beta-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone.
Sandeep TC; Andrew R; Homer NZ; Andrews RC; Smith K; Walker BR
Diabetes; 2005 Mar; 54(3):872-9. PubMed ID: 15734867
[TBL] [Abstract][Full Text] [Related]
2. Body fat distribution and cortisol metabolism in healthy men: enhanced 5beta-reductase and lower cortisol/cortisone metabolite ratios in men with fatty liver.
Westerbacka J; Yki-Järvinen H; Vehkavaara S; Häkkinen AM; Andrew R; Wake DJ; Seckl JR; Walker BR
J Clin Endocrinol Metab; 2003 Oct; 88(10):4924-31. PubMed ID: 14557475
[TBL] [Abstract][Full Text] [Related]
3. Acute in vivo regulation of 11beta-hydroxysteroid dehydrogenase type 1 activity by insulin and intralipid infusions in humans.
Wake DJ; Homer NZ; Andrew R; Walker BR
J Clin Endocrinol Metab; 2006 Nov; 91(11):4682-8. PubMed ID: 16954164
[TBL] [Abstract][Full Text] [Related]
4. Local and systemic impact of transcriptional up-regulation of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity.
Wake DJ; Rask E; Livingstone DE; Söderberg S; Olsson T; Walker BR
J Clin Endocrinol Metab; 2003 Aug; 88(8):3983-8. PubMed ID: 12915696
[TBL] [Abstract][Full Text] [Related]
5. Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonists on 11beta-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue in men.
Wake DJ; Stimson RH; Tan GD; Homer NZ; Andrew R; Karpe F; Walker BR
J Clin Endocrinol Metab; 2007 May; 92(5):1848-56. PubMed ID: 17327378
[TBL] [Abstract][Full Text] [Related]
6. Effects of Obesity and Insulin on Tissue-Specific Recycling Between Cortisol and Cortisone in Men.
Anderson AJ; Andrew R; Homer NZM; Hughes KA; Boyle LD; Nixon M; Karpe F; Stimson RH; Walker BR
J Clin Endocrinol Metab; 2021 Mar; 106(3):e1206-e1220. PubMed ID: 33270115
[TBL] [Abstract][Full Text] [Related]
7. Tissue production of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 and metabolic disease.
Walker BR; Andrew R
Ann N Y Acad Sci; 2006 Nov; 1083():165-84. PubMed ID: 17148739
[TBL] [Abstract][Full Text] [Related]
8. 11 beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
Wake DJ; Walker BR
Mol Cell Endocrinol; 2004 Feb; 215(1-2):45-54. PubMed ID: 15026174
[TBL] [Abstract][Full Text] [Related]
9. Is 11beta-hydroxysteroid dehydrogenase type 1 a therapeutic target? Effects of carbenoxolone in lean and obese Zucker rats.
Livingstone DE; Walker BR
J Pharmacol Exp Ther; 2003 Apr; 305(1):167-72. PubMed ID: 12649365
[TBL] [Abstract][Full Text] [Related]
10. Tissue-specific dysregulation of cortisol metabolism in human obesity.
Rask E; Olsson T; Söderberg S; Andrew R; Livingstone DE; Johnson O; Walker BR
J Clin Endocrinol Metab; 2001 Mar; 86(3):1418-21. PubMed ID: 11238541
[TBL] [Abstract][Full Text] [Related]
11. The contribution of visceral adipose tissue to splanchnic cortisol production in healthy humans.
Andrew R; Westerbacka J; Wahren J; Yki-Järvinen H; Walker BR
Diabetes; 2005 May; 54(5):1364-70. PubMed ID: 15855321
[TBL] [Abstract][Full Text] [Related]
12. Effects of the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes.
Andrews RC; Rooyackers O; Walker BR
J Clin Endocrinol Metab; 2003 Jan; 88(1):285-91. PubMed ID: 12519867
[TBL] [Abstract][Full Text] [Related]
13. Cortisol release from adipose tissue by 11beta-hydroxysteroid dehydrogenase type 1 in humans.
Stimson RH; Andersson J; Andrew R; Redhead DN; Karpe F; Hayes PC; Olsson T; Walker BR
Diabetes; 2009 Jan; 58(1):46-53. PubMed ID: 18852329
[TBL] [Abstract][Full Text] [Related]
14. Carbenoxolone treatment ameliorated metabolic syndrome in WNIN/Ob obese rats, but induced severe fat loss and glucose intolerance in lean rats.
Prasad Sakamuri SS; Sukapaka M; Prathipati VK; Nemani H; Putcha UK; Pothana S; Koppala SR; Ponday LR; Acharya V; Veetill GN; Ayyalasomayajula V
PLoS One; 2012; 7(12):e50216. PubMed ID: 23284633
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 in obesity.
Wake DJ; Walker BR
Endocrine; 2006 Feb; 29(1):101-8. PubMed ID: 16622297
[TBL] [Abstract][Full Text] [Related]
16. [Modulation of tissue exposure to cortisol, new perspective for reducing the metabolic risk associated with obesity].
Iovino A; Scheen AJ
Rev Med Liege; 2010 Mar; 65(3):140-6. PubMed ID: 20411818
[TBL] [Abstract][Full Text] [Related]
17. Extra-adrenal regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1: physiological regulator and pharmacological target for energy partitioning.
Walker BR
Proc Nutr Soc; 2007 Feb; 66(1):1-8. PubMed ID: 17343766
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of 11β-hydroxysteroid dehydrogenase 1 by carbenoxolone affects glucose homeostasis and obesity in db/db mice.
Dhanesha N; Joharapurkar A; Shah G; Kshirsagar S; Dhote V; Sharma A; Jain M
Clin Exp Pharmacol Physiol; 2012 Jan; 39(1):69-77. PubMed ID: 22060140
[TBL] [Abstract][Full Text] [Related]
19. Human adipose tissue under in vitro inhibition of 11beta-hydroxysteroid dehydrogenase type 1: differentiation and metabolism changes.
Bader T; Zoumakis E; Friedberg M; Hiroi N; Chrousos GP; Hochberg Z
Horm Metab Res; 2002; 34(11-12):752-7. PubMed ID: 12660894
[TBL] [Abstract][Full Text] [Related]
20. 11β-hydroxysteroid dehydrogenase types 1 and 2 activity in subcutaneous adipose tissue in humans: implications in obesity and diabetes.
Dube S; Norby BJ; Pattan V; Carter RE; Basu A; Basu R
J Clin Endocrinol Metab; 2015 Jan; 100(1):E70-6. PubMed ID: 25303491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
